242 related articles for article (PubMed ID: 23471434)
1. Stable tumor vessel normalization with pO₂ increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment.
Kieda C; El Hafny-Rahbi B; Collet G; Lamerant-Fayel N; Grillon C; Guichard A; Dulak J; Jozkowicz A; Kotlinowski J; Fylaktakidou KC; Vidal A; Auzeloux P; Miot-Noirault E; Beloeil JC; Lehn JM; Nicolau C
J Mol Med (Berl); 2013 Jul; 91(7):883-99. PubMed ID: 23471434
[TBL] [Abstract][Full Text] [Related]
2. Tumour angiogenesis normalized by myo-inositol trispyrophosphate alleviates hypoxia in the microenvironment and promotes antitumor immune response.
El Hafny-Rahbi B; Brodaczewska K; Collet G; Majewska A; Klimkiewicz K; Delalande A; Grillon C; Kieda C
J Cell Mol Med; 2021 Apr; 25(7):3284-3299. PubMed ID: 33624446
[TBL] [Abstract][Full Text] [Related]
3. Antihypoxic Potentiation of Standard Therapy for Experimental Colorectal Liver Metastasis through Myo-Inositol Trispyrophosphate.
Limani P; Linecker M; Kachaylo E; Tschuor C; Kron P; Schlegel A; Ungethuem U; Jang JH; Georgiopoulou S; Nicolau C; Lehn JM; Graf R; Humar B; Clavien PA
Clin Cancer Res; 2016 Dec; 22(23):5887-5897. PubMed ID: 27489288
[TBL] [Abstract][Full Text] [Related]
4. Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy.
Raykov Z; Grekova SP; Bour G; Lehn JM; Giese NA; Nicolau C; Aprahamian M
Int J Cancer; 2014 Jun; 134(11):2572-82. PubMed ID: 24214898
[TBL] [Abstract][Full Text] [Related]
5. Tumour suppressor PTEN activity is differentially inducible by myo-inositol phosphates.
Grzymajlo K; El Hafny-Rahbi B; Kieda C
J Cell Mol Med; 2023 Mar; 27(6):879-890. PubMed ID: 36852461
[TBL] [Abstract][Full Text] [Related]
6. Suppression of hypoxia-induced HIF-1alpha and of angiogenesis in endothelial cells by myo-inositol trispyrophosphate-treated erythrocytes.
Kieda C; Greferath R; Crola da Silva C; Fylaktakidou KC; Lehn JM; Nicolau C
Proc Natl Acad Sci U S A; 2006 Oct; 103(42):15576-81. PubMed ID: 17028170
[TBL] [Abstract][Full Text] [Related]
7. Increasing the oxygen load by treatment with myo-inositol trispyrophosphate reduces growth of colon cancer and modulates the intestine homeobox gene Cdx2.
Derbal-Wolfrom L; Pencreach E; Saandi T; Aprahamian M; Martin E; Greferath R; Tufa E; Choquet P; Lehn JM; Nicolau C; Duluc I; Freund JN
Oncogene; 2013 Sep; 32(36):4313-8. PubMed ID: 23045284
[TBL] [Abstract][Full Text] [Related]
8. Failure of Inositol Trispyrophosphate to Enhance Highly Effective Radiotherapy of GL261 Glioblastoma in Mice.
Iyengar S; Schwartz D
Anticancer Res; 2017 Mar; 37(3):1121-1125. PubMed ID: 28314273
[TBL] [Abstract][Full Text] [Related]
9. Oxygen therapeutic window induced by myo-inositol trispyrophosphate (ITPP)-Local pO2 study in murine tumors.
Krzykawska-Serda M; Szczygieł D; Gaweł S; Drzał A; Szczygieł M; Kmieć MM; Mackiewicz A; Kieda C; Elas M
PLoS One; 2023; 18(5):e0285318. PubMed ID: 37167239
[TBL] [Abstract][Full Text] [Related]
10. Impact of myo-inositol trispyrophosphate (ITPP) on tumour oxygenation and response to irradiation in rodent tumour models.
Tran LB; Cao-Pham TT; Jordan BF; Deschoemaeker S; Heyerick A; Gallez B
J Cell Mol Med; 2019 Mar; 23(3):1908-1916. PubMed ID: 30575283
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of the effect of hypoxia in two different tumor cell models shows the differential involvement of PTEN control of proangiogenic pathways.
Majewska A; Brodaczewska K; Filipiak-Duliban A; Kieda C
Biochem Cell Biol; 2024 Feb; 102(1):47-59. PubMed ID: 37459649
[TBL] [Abstract][Full Text] [Related]
12. Tumor Oxygenation by Myo-Inositol Trispyrophosphate Enhances Radiation Response.
Grgic I; Tschanz F; Borgeaud N; Gupta A; Clavien PA; Guckenberger M; Graf R; Pruschy M
Int J Radiat Oncol Biol Phys; 2021 Jul; 110(4):1222-1233. PubMed ID: 33587991
[TBL] [Abstract][Full Text] [Related]
13. Treatment of hypoxia-dependent cardiovascular diseases by myo-inositol trispyrophosphate (ITPP)-enhancement of oxygen delivery by red blood cells.
Oknińska M; El-Hafny-Rahbi B; Paterek A; Mackiewicz U; Crola-Da Silva C; Brodaczewska K; Mączewski M; Kieda C
J Cell Mol Med; 2020 Feb; 24(3):2272-2283. PubMed ID: 31957267
[TBL] [Abstract][Full Text] [Related]
14. Myo-InositolTrisPyroPhosphate treatment leads to HIF-1α suppression and eradication of early hepatoma tumors in rats.
Aprahamian M; Bour G; Akladios CY; Fylaktakidou K; Greferath R; Soler L; Marescaux J; Egly JM; Lehn JM; Nicolau C
Chembiochem; 2011 Mar; 12(5):777-83. PubMed ID: 21370375
[TBL] [Abstract][Full Text] [Related]
15. Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction.
Stucke-Ring J; Ronnacker J; Brand C; Höltke C; Schliemann C; Kessler T; Schmidt LH; Harrach S; Mantke V; Hintelmann H; Hartmann W; Wardelmann E; Lenz G; Wünsch B; Müller-Tidow C; Mesters RM; Schwöppe C; Berdel WE
Oncotarget; 2016 Dec; 7(50):82458-82472. PubMed ID: 27738341
[TBL] [Abstract][Full Text] [Related]
16. Enhanced exercise capacity in mice with severe heart failure treated with an allosteric effector of hemoglobin, myo-inositol trispyrophosphate.
Biolo A; Greferath R; Siwik DA; Qin F; Valsky E; Fylaktakidou KC; Pothukanuri S; Duarte CD; Schwarz RP; Lehn JM; Nicolau C; Colucci WS
Proc Natl Acad Sci U S A; 2009 Feb; 106(6):1926-9. PubMed ID: 19204295
[TBL] [Abstract][Full Text] [Related]
17. Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery.
Kim SJ; Jung KH; Son MK; Park JH; Yan HH; Fang Z; Kang YW; Han B; Lim JH; Hong SS
Cancer Lett; 2017 Sep; 403():339-353. PubMed ID: 28688971
[TBL] [Abstract][Full Text] [Related]
18. The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels.
Iivanainen E; Lauttia S; Zhang N; Tvorogov D; Kulmala J; Grenman R; Salven P; Elenius K
Microvasc Res; 2009 Dec; 78(3):278-85. PubMed ID: 19596357
[TBL] [Abstract][Full Text] [Related]
19. Loss of Mel-18 induces tumor angiogenesis through enhancing the activity and expression of HIF-1α mediated by the PTEN/PI3K/Akt pathway.
Park JH; Lee JY; Shin DH; Jang KS; Kim HJ; Kong G
Oncogene; 2011 Nov; 30(45):4578-89. PubMed ID: 21602890
[TBL] [Abstract][Full Text] [Related]
20. Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors.
Schneider MA; Linecker M; Fritsch R; Muehlematter UJ; Stocker D; Pestalozzi B; Samaras P; Jetter A; Kron P; Petrowsky H; Nicolau C; Lehn JM; Humar B; Graf R; Clavien PA; Limani P
Nat Commun; 2021 Jun; 12(1):3807. PubMed ID: 34155211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
